WEBINAR: An HEOR playbook for oncology RWE and AI use to support European HTA – July 28, 2026
Learn how global oncology real-world data and AI-enabled evidence generation and analysis can strengthen European HTA submissions under joint clinical assessment.
European oncology market access is changing. Since January 2025, new cancer medicines must undergo EU joint clinical assessments alongside EMA review, while national HTA bodies continue to refine evidence requirements across Member States. For many submissions, teams rely on real-world data to address comparative effectiveness, heterogeneous PICO needs, and compressed dossier timelines.
As demand for faster, higher-quality evidence grows, organizations are also exploring how AI and advanced analytics can support evidence generation and analysis.
Join Flatiron Health and leading biopharma and industry experts to discuss practical strategies for HTA decision-making across Europe.
What you will learn
- How EU joint clinical assessment and national HTA processes are changing evidence expectations for oncology medicines across Member States.
- Where real-world data adds the most value in HTA submissions, from comparator selection to supplementing immature or single-arm trial evidence.
- How multinational oncology real-world data can support both global and country-specific evidence needs in market access planning.
- Practical strategies for proactive evidence planning within compressed joint clinical assessment timelines and across heterogeneous PICO requirements.
- How advanced analytics and AI are being applied to accelerate real-world evidence generation and analysis, and what that means for HTA-ready evidence across Europe.
Speakers
Arun Sujenthiran, MD, FRCS
Senior Medical Director, International Lead, Flatiron Health
Arun Sujenthiran is Clinical Lead at Flatiron Health International, overseeing teams who curate oncology data products across the UK, Germany, and Japan. He works with cross-functional partners to ensure the clinical relevance and scientific rigor of Flatiron’s real-world data offerings. A former uro-oncology surgeon and health outcomes researcher, Arun continues to practice at a London NHS hospital. He earned his medical degree with distinction from Imperial College London and completed an MD(Res) at the Royal College of Surgeons Clinical Effectiveness Unit. His research focuses on using real-world data to improve cancer care and patient outcomes.
Hillary Keenan, PhD, MS
Senior Director, Epidemiology, Global Evidence and Outcomes
Takeda
Hillary Keenan, PhD, MS, is a Senior Director, Epidemiology, Global Evidence and Outcomes, at Takeda. An epidemiologist with more than 20 years of experience, she has built her career across public health, academia, and industry, with expertise in real-world data, as well as genetic and translational epidemiology. Dr Keenan earned her MS in Epidemiology/Biostatistics from the University of Massachusetts, Amherst, and her doctorate in Molecular Epidemiology from the University of Pittsburgh. She spent 14 years on faculty at the Joslin Diabetes Center, Harvard Medical School before joining industry. She now works to demonstrate the relative effectiveness and safety of new therapies and accelerate patient access.
Additional speakers TBC
In association with
If you are interested in partnering with The Evidence Base for future webinars, please contact [email protected].